Sahmri
Business Services · Australia · 201-500 Employees
View Company Info for Free
Overview
Headquarters
You Can't Miss Us North Ter, Adelaide, S...Phone Number
+61 881284000Website
www.sahmri.orgRevenue
$62 MillionIndustry
About Sahmri
Sahmri Org Chart
Is Sahmri your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Sahmri has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Sahmri has new funding data
Earning: See what the market has to say on Sahmri recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Sahmri
Check out if Sahmri is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Sahmri launches new products
Click to see if Sahmri had a recent Job posting/layoffs
Sahmri, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Sahmri as Masked Content
Find 3 more new buyers
Compare Similar Companies to Sahmri
Compare insights from companies similar to Sahmri, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sahmri is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Sahmri is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Sahmri.
Sahmri Tech Stack
A closer look at the technologies used by Sahmri
Sahmri News & Media
First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced the first patient was dosed with lenzilumab in the Precision Approach to Chronic Myelomonocytic Leukemia (‘PREACH-M’) clinical trial being sponsored by the South Australian Health and Medical Research Institute (SAHMRI) and funded by a Medical Research Future Fund grant from the National Health and Medical Research Council of the Australian government to the University of Adelaide. Humanigen is pr
Top Business Services Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Sahmri
Everything we do is geared towards one vision: conducting inspired research that will lead to better health outcomes. SAHMRI draws together more than 800 researchers in a state of the art, purpose-built facility in the west end of Adelaide. Backed by the support of the Federal and State Governments, as well as the three major South Australian unive... Read More